%0 Journal Article
%T 甲状腺相关眼病的治疗进展及生活质量研究<br>Progress in Treatment and Quality of Life of Thyroid-Associated Ophthalmopathy
%A 梁伊日贵
%A 张春香
%J Advances in Clinical Medicine
%P 12264-12270
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.1381718
%X 甲状腺相关眼病(TAO)又称Graves眼病(GO)，常见于Graves病，是一种器官特异性自身免疫性疾病，是成人最常见的眼眶疾病，它会导致眼睛鼓胀、复视、视神经受压和视力丧失，对生活质量有重大影响。TAO的治疗常用糖皮质激素、放疗或手术治疗，此外，新型靶向药物逐渐被开发出来，包括teprotumumab (抗IGF-1R单克隆抗体)和rituximab (抗CD20单克隆抗体)。本文就甲状腺相关眼病治疗进展及生活质量研究进行一简要综述。<br />
Thyroid associated ophthalmopathy (TAO), also known as Graves’ ophthalmopathy (GO), is an or-gan-specific autoimmune disease commonly seen in Graves’ disease. It is the most common orbital disease in adults. Tao causes eye distention, double vision, optic nerve compression and vision loss, which has a significant impact on quality of life. Treatment of TAO is usually treated with glucocor-ticoids, radiotherapy or surgery, and novel targeted drugs are gradually being developed, including teprotumumab (anti-IGF-1R monoclonal antibody) and rituximab (anti-CD20 monoclonal antibody). This article reviews the progress in treatment and quality of life of thyroid related ophthalmopathy.
%K 甲状腺相关眼病，治疗进展，生活质量<br>Thyroid Related Ophthalmopathy
%K Treatment Progress
%K Quality of Life
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=70227